Immunosenescence and herd immunity: With an ever-increasing aging population do we need to rethink vaccine schedules?

Expert Review of Vaccines

Volumn 11, Issue 2, 2012, Pages 167-176

  Lang, Pierre Olivier ^a,b   Aspinall, Richard ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b CRANFIELD UNIVERSITY   (United Kingdom)

Author keywords

aging; elderly; healthy aging; herd immunity; immunosenescence; vaccine effectiveness; vaccine program

Indexed keywords

ANTIBIOTIC AGENT; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE;

AGING; AUTISM; DIPHTHERIA; DISEASE PREDISPOSITION; HEALTH PROGRAM; HEPATITIS B; HERD IMMUNITY; HUMAN; IMMUNE RESPONSE; INFLUENZA; MEASLES; MUMPS; NONHUMAN; PERTUSSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; REVIEW; RUBELLA; SENESCENCE; TETANUS; TREATMENT RESPONSE; VACCINATION;

AGED; AGED, 80 AND OVER; AGING; COMMUNICABLE DISEASE CONTROL; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; MIDDLE AGED; PUBLIC HEALTH; TREATMENT OUTCOME; VACCINES;

EID: 84856854316     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.187     Document Type: Review

References (104)

1. Lutz W, Sanderson W, Scherbov S. Doubling of world population unlikely. Nature 387, 803-805 (1997).
2. Oeppen J, Vaupel JW. Demography. Broken limits to life expectancy. Science 296, 1029-1031 (2002). (Pubitemid 34517101)
3. Fulop T, Larbi A, Witkowski JM et al. Aging, frailty and age-related diseases. Biogerontology 11, 547-563 (2010).
4. Lang PO, Mitchell WA, Lapenna A, Pitts D, Aspinall R. Immunological pathogenesis of main aged-related disease and frailty: Role of immunosenescence. Eur. Geriatric Med. 1, 112-121 (2010).
5. Yong V, Saito Y. Trends in healthy life expectancy in Japan: 1986-2004. Demographic Res. 20, 467-494 (2009).
6. Parker MG, SchÖn P, Lagergren M, Thorslund M. Functional ability in the elderly Swedish population from 1980 to 2005. Eur. J. Ageing 5, 299-309 (2008).
7. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect. Dis. 2, 659-666 (2002).
8. Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin. Infect. Dis. 30, 931-933 (2000). (Pubitemid 32250334)
9. Lang PO, Govind S, Mitchell WA, Siegrist CA, Aspinall R. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing Res. Rev. 10, 389-395 (2011).
10. Influenza vaccines. Wkly Epidemiol. Rec. 80, 279-287 (2005).
11. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163, 693-698 (1991).
12. Henderson FW, Collier AM, Clyde WA Jr, Denny FW. Respiratory-syncytial- virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N. Eng. J. Med. 300, 530-534 (1979). (Pubitemid 9167827)
13. Fulton RB, Varga SM. Effects of aging on the adaptive immune response to respiratory virus infections. Ageing Health 5, 775 (2009).
14. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J. Infect. Dis. 189, 233-238 (2004). (Pubitemid 38147246)
15. Falsey AR, Wlash EE, Hayden FG. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J. Infect. Dis. 185, 1338-1341 (2002). (Pubitemid 34439143)
16. Ghosh S, Champlin R, Couch R et al. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin. Infect. Dis. 29, 553-555 (1999).
17. Glezen PW, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283, 499-505 (2000). (Pubitemid 30062866)
18. Louie JK, Yagi S, Nelson FA et al. Rhinovirus outbreak in a long term care facility for elderly persons associated with unusually high mortality. Clin. Infect. Dis. 41, 262-265 (2005). (Pubitemid 40962510)
19. World Health Organization (WHO). The Centralized Information System for Infectious Diseases (CISID). Geneva, Switzerland (2009).
20. Cabellos C, Verdaguer R, Olmo M et al. Community-acquired bacterial meningitis in elderly patients: Experience over 30 years. Medicine 88, 115-119 (2009).
21. Lang PO, Govind S, Michel JP, Aspinall R, Mitchell WA. Immunosenescence: Implications for vaccination programmes in adults. Maturitas 68, 322-330 (2011).
22. Metersky ML, Dransfield MT, Jackson LA. Determining the optional pneumococcal vaccination in adults: Is there a role for the pneumococcal conjugate vaccine? Chest 138, 486-490 (2010).
23. Michel JP, Lang PO. Promoting life course vaccination. Rejuvenation Res. 14, 75-81 (2011).
24. Van Herck K, Leuridan E, Van Damme P. Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance. Sex Transm. Infect. 83, 426-432 (2007). (Pubitemid 350063839)
25. Weinberg B, Keller M, Fisher KH et al. Decreased antibody titers and booster responses in tick-born encephalitis vaccinees aged 50-90 years. Vaccine 28, 3511-3515 (2010).
26. Romero-Steiner S, Musher DM, Cetron MS et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29, 281-288 (1999). (Pubitemid 29380185)
27. Weinberg A, Zhang JH, Oxman MN et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J. Infect. Dis. 200, 1068-1076 (2009).
28. Aspinall R, Pitts D, Lapenna A, Mitchell WA. Immunity in the elderly: The role of the thymus. J. Comp. Path. 142, S111-S115 (2010).
29. Virgin HW, Wherry JE, Ahmed R. Redefining chronic viral infection. Cell 138, 30-50 (2010).
30. Panda A, Quian F, Mohanty S et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol. 184, 2518-2527 (2010).
31. Frasca D, Diaz A, Romero M et al. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine 28, 8077-8084 (2010).
32. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extreme of age. Nature Immunol. 9, 185-193 (2009).
33. Lesourd B. Nutritional factors and immunological ageing. Proc. Nutr. Soc. 65, 319-325 (2006). (Pubitemid 46323845)
34. Lang PO, Samaras D. Aging adults and seasonal influenza: Does the vitamin D status (h)arm the body? J. Aging Res. 2012, 806198 (2012).
35. Kelley KW, Weigent DA, Kooijman R. Protein hormones and immunity. Brain Behav. Immun. 21, 384-392 (2007). (Pubitemid 46553732)
36. Lang PO, Govind S, Mitchell WA et al. Influenza vaccine effectiveness in aged individuals: The role played by cell-mediated immunity. Eur. Geriatr. Med. 1, 233-238 (2010).
37. McElhaney JE, Xie D, Hager WD et al. T cell responses are better correlates of vaccine protection in the elderly. J. Immunol. 176, 6333-6339 (2006).
38. Frasca D, Riley RL, Blomberg BB. Humoral immune response and B-cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin. Immunol. 17, 378-384 (2005). (Pubitemid 41058769)
39. Grubeck-Loebenstein B, Della Bella S, Iorio AM et al. Immunosenescence and vaccine failure in elderly. Aging Clin. Exp. Res. 21, 201-209 (2009).
40. Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: A comparison of meta-analyses. Eur. J. Epidemiol. 19, 353-363 (2004). (Pubitemid 39005435)
41. Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Lancet 335, 641-645 (1990). (Pubitemid 20092661)
42. John TJ, Samuel R. Herd immunity and herd effect: New insights and definitions. Eur. J. Epidemiol. 16, 601-606 (2000).
43. Reichert TA, Sagaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N. Engl. J. Med. 344, 889-896 (2001). (Pubitemid 32224397)
44. Carman WF, Elder AG, Wallace LA et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: A randomised controlled trial. Lancet 355, 93-97 (2000). (Pubitemid 30068552)
45. Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354, 1455-1463 (2006).
46. Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Eng. J. Med. 348, 1737-1746 (2003). (Pubitemid 36514704)
47. Lang PO. Adverse effects of the herd immunity or when vaccines become deleterious for the epidemiology of infectious diseases. Geriatr. Psychol. Neuropsychiatr. Vieil. 9, 11-19 (2011).
48. Sugaya N, Takeuchi Y. Mass vaccination of schoolchildren against influenza and its impact on the influenza-associated mortality rate among children in Japan. Clin. Infect. Dis. 41, 939-947 (2005). (Pubitemid 41368214)
49. Takahashi M, Nagai M. Estimation of excess mortality associated with influenza epidemics specific for sex, age and cause of death in Japan during 1987-2005. Nippon Eiseigaku Zasshi 63, 5-19 (2008).
50. Blomberg BB, Frasca D, Dunn-Walters D, Human B-cell senescence and pulmonary infections. Open Longev. Sci. (2012) (In Press).
51. Proesmans MJ. Pneumococcal vaccination: Time to move on? Eur. J. Pediatr. 169, 1435-1437 (2010).
52. Messina AF, Katz-Gaynor K, Barton T et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr. Infect. Dis. J. 26, 461-467 (2007). (Pubitemid 46847303)
53. Tanaka M, Vitek CR, Pascual FB et al. Trends in pertussis among infants in the United States, 1980-1999. JAMA 290, 2968-2975 (2003). (Pubitemid 37505529)
54. van Amersfoorth SC, Schouls LM, van der Heide HG et al. Analysis of Bordetella pertussis population in European countries with different vaccination policies. J. Clin. Microbiol. 43, 2837-2843 (2005). (Pubitemid 40827962)
55. Guris D, Strebel PM, Bardenheier B et al. Changing epidemiology of pertussis in the United States: Increasing reported incidence among adolescents and adults, 1990-1996. Clin. Infect. Dis. 28, 1230-1237 (1999). (Pubitemid 29272795)
56. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE. Resurgence of pertussis in Europe. Pediatr. Infect. Dis. J. 24, 761-765 (2005). (Pubitemid 41324882)
57. de Greef SC, Mooi FR, Schellekens JF, de Melker HE. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in the Netherlands. Pediatr. Infect. Dis. J. 27, 218-223 (2008).
58. Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196, 1346-1354 (2007). (Pubitemid 351412007)
59. Pai R, Moore MR, Pilishvili T et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192, 1988-1995 (2005). (Pubitemid 41681898)
60. Byington CL, Korgenski K, Daly J et al. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr. Infect. Dis. J. 25, 250-254 (2006). (Pubitemid 43379067)
61. Pelton SI, Huot H, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26, 468-472 (2007). (Pubitemid 46847304)
62. Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297, 1784-1792 (2007). (Pubitemid 46658647)
63. Steenhoff AP, Shah SS, Ratner AJ et al. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin. Infect. Dis. 42, 907-914 (2006).
64. Thigpen MC, Whitney CG, Messonnier NE et al. Bacterial meningitis in the United States, 1998-2007. N. Engl. J. Med. 364, 2016-2025 (2011).
65. Bonmarin I, Santa-Olalla P, Lévy-Bruhl D. Modeling the impact of vaccination on the epidemiology of varicella zoster virus. Rev. Epidemiol. Sante Publique 56, 323-331 (2008).
66. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N. Eng. J. Med. 356, 1338-1343 (2007). (Pubitemid 46513299)
67. Lang PO, Michel JP. Herpes Zoster vaccine: what are the potential benefits for the ageing and older adults? Eur. Geriatr. Med. 2(3), 134-139 (2011).
68. Yoshikawa TT. Perspective: Aging and infectious diseases: Past, present, and future. J. Infect. Dis. 176, 1053-1057 (1997). (Pubitemid 27411050)
69. Poland GA, Jacobson RM, Ovsyannikova IG. Trends affecting the future of vaccine development and delivery: The role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics. Vaccine 27, 3240-3244 (2009).
70. Poland GA, Belmin J, Langley J, Michel JP, Van Damme P, Wicker S. A global prescription for adult immunization: Time is catching up with us. Vaccine 28, 7137-7139 (2010).
71. Poland GA, Jacobson RM. The age-old struggle against the antivaccinationists. N. Eng. J. Med. 364, 97-99 (2011).
72. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Eng. J. Med. 348, 1546-1554 (2003). (Pubitemid 36437931)
73. Michel JP, Chidiac C, Grubeck- Loebenstein B et al. Advocating vaccination of adults aged 60 years and older in Western Europe: Statement by the joint Vaccine Working Group of the European Union Geriatric Medicine Society and the International Association of Gerontology and Geriatrics - European Region. Rejuvenation Res. 12, 127-135 (2009).
74. Baeyens JP, Lang PO, Michel JP. Willingness to vaccinate and to be vaccinated in adults. Ageing Clin. Exp. Res. 21, 244-249 (2009).
75. Vaughn JA, Miller RA. Update on immunizations in adults. Am. Fam. Physic. 84, 1015-1020 (2011).
76. Halperin SA. Pertussis - a disease and vaccine for all ages. N. Engl. J. Med. 353, 1615-1617 (2005). (Pubitemid 41434642)
77. Moxon ER, Siegrist CA. The next decade of vaccines: Societal and scientific challenges. Lancet 378, 348-359 (2011).
78. Rhen M, Eriksson S, Clements M, BergstrÖm S, Normark SJ. The basis of persistent bacterial infections. Trends Microbiol. 11, 80-86 (2003). (Pubitemid 36207504)
79. Jones KE, Patel NG, Levy MA et al. Global trends in emerging infectious diseases. Nature 451, 990-993 (2008). (Pubitemid 351301726)
80. Nash D, Mostashari F, Fine A et al. The outbreak of West Nile virus infection in the New York City area in 1999. N. Engl. J. Med. 344, 1807-1814 (2001). (Pubitemid 32538693)
81. Berner YN, Lang R, Chowers MY. Outcome of West Nile fever in older adults. J. Am. Geriatr. Soc. 50, 1844-1846 (2002). (Pubitemid 35291728)
82. Cliff A, Haggett P. Time, travel and infection. Br. Med. Bull. 69, 87-99 (2004).
83. Stuck AE, Kjaricha K, Dapp U et al. Development, feasibility and performance of a health appraisal questionnaire for older persons. BMC Med. Res. Methodol. 7, 1 (2007).
84. Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 10, 837-852 (2009).
85. Sette A, Rappuoli R. Reverse vaccinology: Developing vaccines in the era of genomics. Immunity 33, 530-541 (2010).
86. Centers for Disease Control and Prevention (CDC). Update: mumps outbreak - New York and New Jersey, 2009-2010. MMWR Morb. Mortal Wkly Rep. 59, 125-129 (2010).
87. Centers for Disease Control and Prevention (CDC). Impact of vaccine universally recommended for children - United States, 1990-1998. MMWR Morb. Mortal Wkly Rep. 48, 243-248 (1999).
88. Wolfe RM, Sharp LK, Anti-vaccinationists past and present. BMJ 325, 430-432 (2002). (Pubitemid 34969795)
89. Wakefield AJ, Murch SH, Anthony A et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351, 637-641 (1998). (Pubitemid 28098447)
90. World Health Organization (WHO). Outbreak news: measles outbreaks in Europe. Wkly Epidemiol. Rec. 86, 173-176 (2011).
91. Hambleton S, Arvin AM. Chickenpox party or varicella vaccine? Adv. Exp. Med. Biol. 568, 11-24 (2005).
92. Bayer R. The continuing tensions between individual rights and public health. Taking point on public health versus civil liberties. EMBO Rep. 8, 1099-1103 (2007). (Pubitemid 350201723)
93. Parodi V, de Florentiis D, Martini M, Ansaldi F. Inactivated influenza vaccines: Recent progress and implication for the elderly. Drugs Ageing 28, 93-106 (2011).
94. Paccalin M, Weinberger B, Nicolas JF, Van Damme P, Mégard Y. The intradermal vaccination route - an attractive opportunity for influenza vaccination in the elderly Eur. Geriatr. Med. 1, 82-87 (2010).
95. Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated influenza vaccine for person aged < or = 65 years (Fluzone High-Dose) and guidance for use - United States. MMWR Morb. Mortal Wkly Rep. 59, 485-486 (2010).
96. Ansaldi F, Canepa P, Parodi V et al. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection. Vaccine 27, 3345-3348 (2009).
97. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J. Virol. 75, 12182-12187 (2001). (Pubitemid 33115891)
98. 8+CD28- T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J. Immunol. 168, 5893-5899 (2002). (Pubitemid 34556178)
99. Frasca D, Diaz A, Romera M, Landin AM, Blomberg BB. Age effects on B cells and humoral immunity in humans. Ageing Res. Rev. 10, 330-335 (2011).
100. Lang PO, Mitchell WA, Govind S, Aspinall R. Real time-PCR assay estimating the naive T-cell pool in whole blood and dried blood spot samples: Pilot study in young adults. J. Immunol. Methods 369, 133-140 (2011).
101. Mitchell WA, Lang PO, Aspinall R. Tracing thymic output in older individuals. Clin. Exp. Immunol. 161, 497-503 (2010).
102. Hazenberg MD, Borghans JAM, de Boer DJ, Miedema F. Thymic output: A bad TREC record. Nat. Immunol. 4, 97-99 (2003). (Pubitemid 36193005)
103. Aspinall R, Pido-Lopez J, Imami N et al. Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination. Rejuvenation Res. 10(1), 5-17 (2007). (Pubitemid 46449428)
104. Govind S, Lapenna A, Lang PO, Aspinall R. Immunotherapy of immunosenescence: who, how and when. Open Longev. Sci. (2012) (In Press).